Publications scientifiques et présentations
Ces publications scientifiques et présentations sont proposées à des fins de formation uniquement. Elles peuvent mentionner ou discuter des produits de DBV Technologies en cours de développement, et qui ne sont approuvés pour commercialisation par aucune autorité règlementaire ou de santé dans aucun pays du monde.
Publications importantes
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy: A Randomized Clinical Trial
JAMA Pediatr. 2024; 178(4): 345–353. PMID: 38407859 | doi: 10.1001/jamapediatrics.2023.6630
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
Expert Rev Clin Immunol. Published online February 14, 2024. PMID: 38323337 | doi:10.1080/1744666X.2024.2315221
Epicutaneous immunotherapy with Viaskin™ Peanut in toddlers: a plain language summary
Immunotherapy. 2024;16(1):5-13. PMID: 38112107 | doi:10.2217/imt-2023-0201
Recent advances in epicutaneous immunotherapy and potential applications in food allergy
Front Allergy. 2023;4:1290003. PMID: 37965375 | doi:10.3389/falgy.2023.1290003
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
New England Journal of Medicine 2023; 388:1814-1815 | doi:10.1056/NEJMe2301157
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
J Allergy Clin Immunol Pract. 2021. Nov 27;S2213-2198(21)01295-2. | doi:10.1016/j.jaip.2021.11.017
Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy
Allergy. 2021. Dec;76(12):3835-3838. | doi: 10.1111/all.15083.
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Allergy. 2021. Oct;76(10):3223-3226. | doi: 10.1111/all.14973.
Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. | doi: 10.1016/j.jaip.2020.08.017.
Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. | doi: 10.1016/j.jaip.2020.08.015.
Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results
Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. | doi: 10.1016/j.anai.2020.11.015.
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
The Journal of Allergy and Clinical Immunology. 2020. | doi:10.1016/j.jaci.2020.06.028.
Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years
The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. PMID: 32502548. | doi:10.1016/j.jaip.2020.05.030.
An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial
Allergy & Asthma Proceedings. 2020;41:1-10. PMID: 32539908. | doi:10.2500/aap.2020.41.200047.
Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy
Allergy & Asthma Proceedings. 2020;41:278-284. PMID: 32517847. | doi:10.2500/aap.2020.41.200045
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. PMID: 30794314. | doi:10.1001/jama.2019.1113.
Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity
A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. PMID: 29136445. | doi:10.1001/jama.2017.16591.
Get the Quarterly Newsletter from DBV Technologies Medical Affairs & Clinical Development
Présentations Récentes
Ces résumés ont été approuvés pour présentation à un congrès médical et n’ont pas été soumis à une revue complète par des pairs.
American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting:
Poster Presentations:
- Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study –David Fleischer, M.D. [Poster 082]
- Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study — Amy Scurlock, M.D. [Poster 085]
American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting:
Poster Presentations:
- Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years – Rachel Robison, MD [Abstract 097]
- Effect of Allergy Specialty Care of Healthcare Utilization Among Children with Peanut Allergy in the United States – Matthew Greenhawt, MD [Abstract 120]
- Efficacy of Epicutaneous Immunotherapy with ViaskinTM Peanut for 4-7 Year-Old Peanut-Allergic Children in a Phase 3 Clinical Trial (PEPITES) – David Fleischer, MD [Abstract 71]
Canadian Society of Allergy and Clinical Immunology (CSACI) 2022 Annual Meeting:
Poster Presentations:
- Efficacy of Epicutaneous Immunotherapy with ViaskinTM Peanut for 4-7 Year-Old Peanut-Allergic Children in a Phase 3 Clinical Trial (PEPITES) – David Fleischer, MD [Abstract 71]
American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting:
Oral Presentation:
- EPITOPE Study Results: Phase 3, Randomized, Double-blind, Placebo-controlled Study of Epicutaneous Immunotherapy in Peanut-allergic Toddlers – Matthew Greenhawt, MD [Abstract D019]
Poster Presentation:
- Reduction in Reaction Severity Following 12 Months of Epicutaneous Immunotherapy with Peanut Patch in Toddlers – Terri Brown-Whitehorn, MD [Abstract P183]